Last reviewed · How we verify
Placebo Prednisolone
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma, Adrenal insufficiency.
At a glance
| Generic name | Placebo Prednisolone |
|---|---|
| Also known as | Placebo, solupred, Orapred, oral corticosteroid, Predosone |
| Sponsor | Milton S. Hershey Medical Center |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Prednisolone is a synthetic glucocorticoid that enters cells and binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The term 'Placebo Prednisolone' suggests this may refer to a placebo-controlled formulation or study arm rather than an active drug product.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Allergic reactions and asthma
- Adrenal insufficiency
- Certain hematologic malignancies and lymphomas
Common side effects
- Hyperglycemia / glucose intolerance
- Hypertension
- Osteoporosis / bone loss
- Immunosuppression / increased infection risk
- Insomnia / mood changes
- Weight gain / fluid retention
- Gastrointestinal upset
Key clinical trials
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) (PHASE3)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial (PHASE3)
- Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency (PHASE4)
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (PHASE3)
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (PHASE3)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Prednisolone CI brief — competitive landscape report
- Placebo Prednisolone updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI